Compare KRKR & PFSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRKR | PFSA |
|---|---|---|
| Founded | 2010 | 2009 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Business Services | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.5M | 11.1M |
| IPO Year | 2019 | N/A |
| Metric | KRKR | PFSA |
|---|---|---|
| Price | $4.75 | $0.19 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 3.4K | ★ 6.8M |
| Earning Date | 09-26-2025 | 11-19-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $30,966,526.00 | N/A |
| Revenue This Year | $182.55 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 122.22 |
| 52 Week Low | $2.76 | $0.12 |
| 52 Week High | $21.36 | $12.76 |
| Indicator | KRKR | PFSA |
|---|---|---|
| Relative Strength Index (RSI) | 40.73 | N/A |
| Support Level | $4.11 | N/A |
| Resistance Level | $4.85 | N/A |
| Average True Range (ATR) | 0.26 | 0.00 |
| MACD | 0.00 | 0.00 |
| Stochastic Oscillator | 43.87 | 0.00 |
36KR Holdings Inc is a holding company and conducts its business mainly through its subsidiaries, a VIE, and subsidiaries of the VIE. The Group is engaging in providing content and business services to new economy participants in the PRC. Its content production process includes content creation, content editing, screening and monitoring, and content distribution. The Group mainly generates revenues from providing online advertising services, enterprise value-added services, and subscription services. The Group's principal operations and geographic markets are substantially located in PRC.
Profusa Inc is a clinical-stage digital health and medical technology company focused on developing biosensing solutions to improve health outcomes for patients with a variety of different diseases and conditions. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term.